Physician profile
James E Gleason
NPI 1780649368
$5,800.82
in general payments reported to CMS, 2019-2025
30 companies · $891 in 2025
The $891 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $1,109 · 2021: $827 · 2022: $501 · 2023: $710 · 2024: $1,056 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,656.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,127.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $884.04 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $747.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $542.89 | 2019-2025 | Ozempic, Rybelsus |
| Viiv Healthcare Company | $442.25 | 2022-2025 | Dovato, Cabenuva |
| Sanofi-Aventis U.S. LLC | $413.45 | 2019-2023 | |
| Abbvie INC. | $326.67 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $249.18 | 2019-2023 | Verquvo, Belsomra |
| Pfizer INC. | $229.33 | 2020-2024 | |
| Amarin Pharma, INC. | $140.80 | 2020-2021 | |
| Gilead Sciences, INC. | $85.04 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $58.16 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $48.54 | 2023-2025 | Quviviq, Quviviq |
| Hikma Pharmaceuticals USA | $46.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $46.38 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $44.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.64 | 2021 | |
| Astellas Pharma US INC | $43.24 | 2019-2024 | Veozah |
| Abbott Laboratories | $39.59 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $37.62 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $32.22 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $31.53 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Eyevance Pharmaceuticals LLC | $24.68 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.92 | 2025 | |
| Eisai INC. | $18.37 | 2022 | |
| Mannkind Corporation | $18.02 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $16.72 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2024 | Zoryve |
| Ironwood Pharmaceuticals, INC | $14.14 | 2019 | |
| Avion Pharmaceuticals | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gleason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.